Kras(g12c) Inhibitors on the Horizon

dc.contributor.author Çağır, Ali
dc.contributor.author Azmi, Asfar S.
dc.coverage.doi 10.4155/fmc-2018-0304
dc.date.accessioned 2020-07-25T22:12:41Z
dc.date.available 2020-07-25T22:12:41Z
dc.date.issued 2019
dc.description.abstract RAS proteins (the four isoforms KRAS4A, KRAS4B, NRAS and HRAS encoded by three genes KRAS, NRAS and HRAS) act as molecular switches that when activated drive several key cellular processes such as cell growth, proliferation and survival [1]. In normal cells, RAS activity is under tight control by the precise activation (binding to GTP) and inactivation (GTP hydrolysis to GDP) [1]. As with other critical proteins, it is not at all surprising to note that the gene encoding the RAS protein isoforms is found mutated or altered in a significant proportion of tumors [2]. Mutant RAS loses its ability to hydrolyze GTP and remains in a permanently activated state (bound to GTP) leading to uncontrolled growth. en_US
dc.identifier.doi 10.4155/fmc-2018-0304 en_US
dc.identifier.doi 10.4155/fmc-2018-0304
dc.identifier.issn 1756-8919
dc.identifier.issn 1756-8927
dc.identifier.scopus 2-s2.0-85067600007
dc.identifier.uri https://doi.org/10.4155/fmc-2018-0304
dc.identifier.uri https://hdl.handle.net/11147/9488
dc.language.iso en en_US
dc.publisher Future Science en_US
dc.relation.ispartof Future Medicinal Chemistry en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject Inhibitors en_US
dc.subject KRAS en_US
dc.subject KRAS(G12C) en_US
dc.subject KRAS(G12D) en_US
dc.subject RAS en_US
dc.subject Therapy resistance en_US
dc.title Kras(g12c) Inhibitors on the Horizon en_US
dc.type Editorial en_US
dspace.entity.type Publication
gdc.author.institutional Çağır, Ali
gdc.bip.impulseclass C4
gdc.bip.influenceclass C5
gdc.bip.popularityclass C4
gdc.coar.access open access
gdc.coar.type text::journal::editorial
gdc.collaboration.industrial true
gdc.description.department İzmir Institute of Technology. Chemistry en_US
gdc.description.endpage 925 en_US
gdc.description.issue 9 en_US
gdc.description.publicationcategory Diğer en_US
gdc.description.scopusquality Q3
gdc.description.startpage 923 en_US
gdc.description.volume 11 en_US
gdc.description.wosquality Q2
gdc.identifier.openalex W2947517655
gdc.identifier.pmid 31140867
gdc.identifier.wos WOS:000474891700001
gdc.index.type WoS
gdc.index.type Scopus
gdc.index.type PubMed
gdc.oaire.accesstype BRONZE
gdc.oaire.diamondjournal false
gdc.oaire.impulse 6.0
gdc.oaire.influence 2.9778857E-9
gdc.oaire.isgreen false
gdc.oaire.keywords Proto-Oncogene Proteins p21(ras)
gdc.oaire.keywords Small Molecule Libraries
gdc.oaire.keywords Drug Development
gdc.oaire.keywords Drug Discovery
gdc.oaire.keywords Animals
gdc.oaire.keywords Humans
gdc.oaire.keywords Point Mutation
gdc.oaire.keywords Guanosine Triphosphate
gdc.oaire.popularity 7.3510273E-9
gdc.oaire.publicfunded false
gdc.oaire.sciencefields 0301 basic medicine
gdc.oaire.sciencefields 0303 health sciences
gdc.oaire.sciencefields 03 medical and health sciences
gdc.openalex.collaboration International
gdc.openalex.fwci 1.15739108
gdc.openalex.normalizedpercentile 0.77
gdc.opencitations.count 7
gdc.plumx.crossrefcites 7
gdc.plumx.mendeley 7
gdc.plumx.pubmedcites 7
gdc.plumx.scopuscites 9
gdc.scopus.citedcount 9
gdc.wos.citedcount 8
relation.isAuthorOfPublication.latestForDiscovery 95611ee0-9a5b-4ec8-90ea-22896ec18aa9
relation.isOrgUnitOfPublication.latestForDiscovery 9af2b05f-28ac-4011-8abe-a4dfe192da5e

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Name:
fmc-2018-0304.pdf
Size:
165.38 KB
Format:
Adobe Portable Document Format